Chobanian Aram V, Bakris George L, Black Henry R, Cushman William C, Green Lee A, Izzo Joseph L, Jones Daniel W, Materson Barry J, Oparil Suzanne, Wright Jackson T, Roccella Edward J
Boston University School of Medicine, Boston, Mass, USA.
Hypertension. 2003 Dec;42(6):1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2. Epub 2003 Dec 1.
The National High Blood Pressure Education Program presents the complete Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Like its predecessors, the purpose is to provide an evidence-based approach to the prevention and management of hypertension. The key messages of this report are these: in those older than age 50, systolic blood pressure (BP) of greater than 140 mm Hg is a more important cardiovascular disease (CVD) risk factor than diastolic BP; beginning at 115/75 mm Hg, CVD risk doubles for each increment of 20/10 mm Hg; those who are normotensive at 55 years of age will have a 90% lifetime risk of developing hypertension; prehypertensive individuals (systolic BP 120-139 mm Hg or diastolic BP 80-89 mm Hg) require health-promoting lifestyle modifications to prevent the progressive rise in blood pressure and CVD; for uncomplicated hypertension, thiazide diuretic should be used in drug treatment for most, either alone or combined with drugs from other classes; this report delineates specific high-risk conditions that are compelling indications for the use of other antihypertensive drug classes (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, calcium channel blockers); two or more antihypertensive medications will be required to achieve goal BP (<140/90 mm Hg, or <130/80 mm Hg) for patients with diabetes and chronic kidney disease; for patients whose BP is more than 20 mm Hg above the systolic BP goal or more than 10 mm Hg above the diastolic BP goal, initiation of therapy using two agents, one of which usually will be a thiazide diuretic, should be considered; regardless of therapy or care, hypertension will be controlled only if patients are motivated to stay on their treatment plan. Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician's judgment remains paramount.
国家高血压教育计划发布了《美国国家联合委员会关于高血压预防、检测、评估及治疗的第七次报告》全文。与之前的报告一样,其目的是提供一种基于证据的高血压预防和管理方法。本报告的关键信息如下:在50岁以上人群中,收缩压(BP)高于140 mmHg比舒张压是更重要的心血管疾病(CVD)危险因素;从115/75 mmHg起,CVD风险随血压每升高20/10 mmHg而翻倍;55岁时血压正常的人一生中患高血压的风险为90%;高血压前期个体(收缩压120 - 139 mmHg或舒张压80 - 89 mmHg)需要通过促进健康的生活方式改变来预防血压逐步升高和CVD;对于单纯性高血压,大多数情况下噻嗪类利尿剂应作为药物治疗的首选,可单独使用或与其他类药物联合使用;本报告明确了特定的高危情况,这些情况是使用其他抗高血压药物类(血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、β受体阻滞剂、钙通道阻滞剂)的有力指征;糖尿病和慢性肾病患者需要两种或更多种抗高血压药物才能使血压达到目标值(<140/90 mmHg,或<130/80 mmHg);对于血压高于收缩压目标值20 mmHg以上或高于舒张压目标值10 mmHg以上的患者,应考虑开始使用两种药物进行治疗,其中一种通常为噻嗪类利尿剂;无论采用何种治疗或护理措施,只有患者有动力坚持治疗方案,高血压才能得到控制。积极的体验、对临床医生的信任和同理心可提高患者的动力和满意度。本报告仅供参考,委员会仍认识到负责医生的判断至关重要。